Whilst ER expression was only prognostic in the subgroup of women with pancreatic cancer in unadjusted analysis, stromal PR positivity conferred a contrasting prognostic value dependent on KRAS mutation status in the entire cohort, and in particular in women. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.